Apogee Therapeutics (NASDAQ:APGE) Hits New 52-Week High – What’s Next?

Posted by Francis Steltz on Jul 27th, 2026

Shares of Apogee Therapeutics Inc. (NASDAQ:APGE – Get Free Report) reached a new 52-week high during trading on Monday . The stock traded as high as $134.40 and last traded at $134.4450, with a volume of 460331 shares traded. The stock had previously closed at $134.28.

Analyst Upgrades and Downgrades

APGE has been the subject of a number of recent analyst reports. Mizuho restated a “neutral” rating and issued a $135.00 price objective (up from $110.00) on shares of Apogee Therapeutics in a research report on Wednesday, June 24th. Canaccord Genuity Group downgraded Apogee Therapeutics from a “buy” rating to a “hold” rating and lifted their price target for the company from $130.00 to $135.11 in a research note on Monday, June 22nd. Wedbush lowered Apogee Therapeutics from an “outperform” rating to a “neutral” rating and set a $135.00 price objective on the stock. in a report on Monday, June 22nd. TD Cowen cut Apogee Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 23rd. Finally, Citigroup downgraded Apogee Therapeutics from a “buy” rating to a “neutral” rating and raised their target price for the company from $125.00 to $135.00 in a report on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $121.25.

Read Our Latest Analysis on APGE

Apogee Therapeutics Price Performance

The firm’s 50-day moving average price is $108.57 and its 200 day moving average price is $88.09. The firm has a market capitalization of $8.31 billion, a price-to-earnings ratio of -31.02 and a beta of 0.32.

Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.01. On average, analysts predict that Apogee Therapeutics Inc. will post -4.45 earnings per share for the current fiscal year.

Insider Activity

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 80,000 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $132.54, for a total value of $10,603,200.00. Following the transaction, the chief executive officer directly owned 1,015,987 shares in the company, valued at approximately $134,658,916.98. This represents a 7.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Carl Dambkowski sold 26,400 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $132.60, for a total transaction of $3,500,640.00. Following the completion of the transaction, the insider directly owned 179,248 shares of the company’s stock, valued at approximately $23,768,284.80. This represents a 12.84% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 182,900 shares of company stock valued at $21,711,585 in the last three months. 24.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of APGE. TD Asset Management Inc increased its stake in Apogee Therapeutics by 55.3% in the fourth quarter. TD Asset Management Inc now owns 129,290 shares of the company’s stock valued at $9,759,000 after purchasing an additional 46,050 shares during the last quarter. Banque Pictet & Cie SA acquired a new stake in Apogee Therapeutics in the 4th quarter worth about $3,155,000. Vanguard Group Inc. boosted its stake in Apogee Therapeutics by 27.3% in the 4th quarter. Vanguard Group Inc. now owns 2,857,824 shares of the company’s stock worth $215,709,000 after buying an additional 612,193 shares during the last quarter. Pictet Asset Management Holding SA purchased a new stake in Apogee Therapeutics in the 4th quarter valued at about $23,616,000. Finally, Geode Capital Management LLC grew its holdings in Apogee Therapeutics by 18.7% in the 4th quarter. Geode Capital Management LLC now owns 1,059,085 shares of the company’s stock valued at $79,957,000 after buying an additional 166,882 shares during the period. 79.04% of the stock is currently owned by institutional investors and hedge funds.

About Apogee Therapeutics

(Get Free Report)

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.